Skip to main content

Table 4 Baseline characteristics and change in AAD, DAD and PWV after 1 year treatment with RAAS inhibition in 25 subjects

From: Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes

  Baseline Follow up P value
Age 64.2 ± 11.8   
Male gender, N (%) 22 (88%)   
Body mass index, kg/m2 29.1 ± 3.4   
Duration of diabetes, years 5.2 ± 4.5   
HbA1c, % 7.6 ± 1.5   
HbA1c, mmol/mol 60.1 ± 17.7   
Median HbA1c since diagnosis, mmol/mol 63.4 ± 17.6   
Maximum HbA1c since diagnosis, mmol/mol 86.6 ± 25.6   
24 h systolic BP, mmHg 136.7 ± 19.3 131.6 ± 20.9 0.12
24 h diastolic BP, mmHg 72.9 ± 10.1 70.7 ± 11.1 0.07
Total cholesterol, mmol/L 4.1 ± 1.0   
Smoking, N (%) 4 (16%)   
Serum aldosterone, pmol/L 337.0 ± 190.8 238.8 ± 138.2 0.11
AAD (10−3 mmHg−1) 1.51 ± 1.15 1.97 ± 1.07 0.007
DAD (10−3 mmHg−1) 1.98 ± 1.29 1.96 ± 1.10 0.92
PWV (m/s) 8.95 ± 2.60 8.33 ± 3.58 0.42
  1. Significant associations in italics
  2. Abbreviations as in Table 1